Outpatient Lung Impedance-Guided Preventive Therapy in Patients With Chronic Heart Failure (CHF)

Hillel Yaffe Medical Center300 enrolled

Overview

Patients suffering from Chronic Heart Failure (CHF) are hospitalized for acute heart failure (AHF) several times a year. Currently, we have no method for prediction of future developments of AHF. In our center we have investigated the monitoring of lung impedence as a predictor for future deterioration. It was found that a decrease in lung impedence of more than 15% from normal value predicts AHF development with sensitivity of 98%. In this study we try to prove the hypothesis that preventive treatment according to lung impedence value may prevent future hospitalizations for AHF and improve clinical outcome. Patients recruited by year: 2011 - 50; 2012 - 25; 2013 - 35; 2014 - 30; 2015 - 50; 2016 - 5

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Enrollment

300

Conditions

Chronic Congestive Heart Failure

Interventions

One hundred fifty patients with CHF will be treated according to common practice and values of lung impedance

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients suffering from CHF, NYHA II-IV class * LV lower than 35% to LV lower than 45% Exclusion Criteria: * Patients with additional disease with life-expectancy of less than 2 years

Locations (1)

Hillel Yaffe Medical Center

Hadera, Israel

RECRUITING

Outcomes

Primary Outcomes

Reduction of hospitalization for acute heart failure

Time frame: Five years

Secondary Outcomes

Improved clinical outcome for CHF patients

Time frame: Five years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.